ChAdOx1 85A Aerosol Versus Intramuscular Vaccination in Healthy Adults (TB039)

Conditions:   Mycobacterium Tuberculosis, Protection Against;   Tuberculosis Interventions:   Biological: ChadOx1 85A - aerosol;   Biological: ChadOx1 85A - IM Sponsors:   François Spertini;   University of Oxford Recruiting
Source: - Category: Research Source Type: clinical trials

Related Links:

AbstractThe interleukin (IL)-12/interferon(IFN) γ axis plays an important role in the control of mycobacterial diseases as demonstrated by the increased susceptibility to mycobacterial species in patients with an inborn error of the IL-12-dependent IFNγ immunity. Here, we report a novel mutation in theIL-12R β1 gene in a female Pakistani patient who was born in a consanguineous marriage and developed severe bacille Calmette –Guérin (BCG) infection and recurrent tuberculosis. After reviewing the patient’s clinical records, she was investigated for IL-12/IFNγ defects using enzyme-lin...
Source: Immunologic Research - Category: Allergy & Immunology Source Type: research
ConclusionThe study signifies the development of a potent therapeutic agent comprising of a complex of anti-TB agent (fatty acids) and antioxidants (carotenoids) from the CGF-extracted spent biomass of C. vulgaris.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Bill Gates, who is currently on a three-day visit to India, said: "Our biggest work has been broadly in the health area helping to get new vaccines introduced, helping to look at innovations in some of the disease-specific areas, like tuberculosis or visceral leishmaniasis (VL) or lymphatic filariasis (LF)."
Source: The Economic Times - Category: Consumer Health News Source Type: news
In conclusion, CASAC adjuvant has great potential to enhance immunogenicity elicited against HspX antigen, which could be an alternative regimen to improve the efficacy of future therapeutic vaccine against Mycobacterium tuberculosis.
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
(Colorado State University) The research led by assistant professors Marcela Henao-Tamayo and Brendan Podell is part of a $44.8 million, seven-year award to the Infectious Disease Research Institute, based in Seattle.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
This article updates our laboratory's systematic search for antigens using bioinformatics tools to clarify the Mtb H37Rv Rv3632 protein's topology and location. This article reports a C-terminal region consisting of peptides 39255 and 39256 (81Thr-Arg114) having high specific binding regarding two infection-related cell lines (A549 and U937); they inhibited mycobacterial entry to U937 cells in a concentration-dependent manner. Rv3632 forms part of the mycobacterial cell envelope, formed by six linear synthetic peptides. Circular dichroism enabled determining the protein's secondary structure. It was also found that peptide...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Children carry a significant tuberculosis disease burden in settings with poor epidemic control and high levels of transmission. Even in high-resource settings, the diagnosis of tuberculosis in children can be challenging, but an accurate diagnosis can be achieved by adopting a systematic approach. This review outlines the general principles of tuberculosis prevention in children, including epidemic control, infection control, contact tracing and preventive therapy, and vaccination; diagnosing pediatric tuberculosis, including specimen collection and microbiological confirmation, highlighting key differences from adults; a...
Source: Clinics in Chest Medicine - Category: Respiratory Medicine Authors: Source Type: research
Exciting clinical results from 2 clinical TB vaccine trials were published in 2018. These, plus promising preclinical candidates form a healthy pipeline of potential vaccines against the leading cause of death from a single infectious agent. The only licensed vaccine, the BCG, continues to be an important tool in protecting against severe forms of TB in children, but has not stopped the diseases causing 1.3 million deaths per year. This review provides an overview of the current TB vaccine pipeline, highlighting recent findings, describes work relating to epidemiologic impact of vaccines, and discusses the future of TB vaccine development.
Source: Clinics in Chest Medicine - Category: Respiratory Medicine Authors: Source Type: research
Treatment of latent tuberculosis infection (LTBI) is an important component of TB control and elimination. LTBI treatment regimens include once-weekly isoniazid plus rifapentine for 3 months, daily rifampin for 4 months, daily isoniazid plus rifampin for 3 –4 months, and daily isoniazid for 6–9 months. Isoniazid monotherapy is efficacious in preventing TB disease, but the rifampin- and rifapentine-containing regimens are shorter and have similar efficacy, adequate safety, and higher treatment completion rates. Novel vaccine strategies, host immuni ty-directed therapies and ultrashort antimicrobial regimens for ...
Source: Clinics in Chest Medicine - Category: Respiratory Medicine Authors: Source Type: research
Diagnosing latent tuberculosis (TB) infection (LTBI) is important globally for TB prevention. LTBI diagnosis requires a positive test for infection and negative evaluation for active disease. Current tests measure an immunologic response and include the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs), T-SPOT.TB and QuantiFERON. The IGRAs are preferred in bacille Calmette-Gu érin–vaccinated populations. The TST is still used when cost or logistical advantages over the IGRAs exist. Both TST and IGRAs have low positive predictive values. Tests that differentiate the TB spectrum and better p...
Source: Clinics in Chest Medicine - Category: Respiratory Medicine Authors: Source Type: research
More News: Research | Tuberculosis | Vaccines